Carrillo ER, Carrillo CJR, Carrillo CLD

Idioma: Español
Referencias bibliográficas: 49
Paginas: 372-378
Archivo PDF: 398.05 Kb.

RESUMEN

Las estatinas son fármacos que se prescriben para el control de la hiperlipidemia y se las considera útiles en la prevención de eventos cardiovasculares. Cada vez hay más pruebas acerca de sus ventajas en la prevención y tratamiento de la sepsis. Se les atribuyen efectos pleiotrópicos antiinflamatorios e inmunomoduladores, inhiben la síntesis de productos de la vía del mevalonato, como isoprenoides y geranilgeranilada. Además, modifican las interacciones intercelulares y la quimiotaxis celular del sistema inmunológico. Las estatinas reducen la liberación de citocinas y proteínas de fase aguda y han demostrado tener propiedades antioxidantes. Con todas estas propiedades, las estatinas se consideran coadyuvantes en el tratamiento de pacientes con sepsis. La gran evidencia existente apoya esta hipótesis en diferentes modelos experimentales y en estudios clínicos. Se requieren más estudios prospectivos y ensayos controlados con asignación al azar que permitan concluir que las estatinas son útiles en el tratamiento de infecciones y sepsis.

REFERENCIAS (EN ESTE ARTÍCULO)

1. Angus DC, Linde-Zwirble WT, Lidicker J, et al. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med 2001;29: 1303-10.

2. Padkin AM, Goldfrad CM, Brady ARM, et al. Epidemiology of severe sepsis occurring in the first 24 hrs in intensive care units in England, Wales, and Northern Ireland. Crit Care Med 2003;31:2332-38.

3. Martin GS, Mannino DM, Eaton S, Moss M. The epidemiology of sepsis in the United States from 1979 through 2000. N Engl J Med 2003;348:1546-54.

4. Carrillo ER, Rivera BS, Carrillo CJ, Carrillo CD. Estatinas, ¿alternativa terapéutica en sepsis? Gac Med Mex 143; 6: 499-503

5. Dellinger RP, Levy MM, Carlet JM, et al. Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock. Crit Care Med 2008;36:296-327.

6. Durthaler JM, Ernst FR, Johnston JA. Managing severe sepsis: a national survey of current practices. Am J Health Syst Pharm 2009;66:45-53.

7. Ferrer R, Artigas A, Levy MM, Blanco J. Improvement in process of care and outcome after a multicenter severe sepsis educational program in Spain. JAMA 2008;21(299): 2294- 303.

8. Carrillo-Esper R. Estatinas en sepsis. Cir Ciruj 2008;76:99- 100.

9. Mach F. Statins as immunomodulators. Transplant Immunol 2002;9:197-200.

10. Terblanche M, Almong Y, Rosenson RS, et al. Statins and sepsis: multiple modifications at multiple levels. Lancet Infect Dis 2007;7:358-68.

11. Takemoto M, Liao JK. Pleiotropic effects of 3-hydroxy-3- methylglutaryl coenzyme a reductase inhibitors. Arterioscl Thromb Vasc Biol 2001;21:1712-19.

12. Goldstein JL, Brown MS. Regulation of the mevalonate pathway. Nature 1990;343:425-30.

13. Zingarelli B. Nuclear factor-κb. Crit Care Med 2005;33:414- 16.

14. Kwak B, Mullhaupt F, Myit S, Mach F. Statins as a newly recognized type of immunomodulator. Nat Med 2000;6:1399-402.

15. Kleemann R, Verschuren L, de Rooij BJ. Evidence for antiinflammatory activity of statins and PPARalpha activators in human C-reactive protein transgenic mice in vivo and in cultured human hepatocytes in vitro. Blood 2004;103:4188-94.

16. Romano M, Diomede L, Sironi M. Inhibition of monocyte chemotactic protein-1 synthesis by statins. Lab Invest 2000;80:1095-100.

17. Weber C, Erl W, Weber KS, Weber PC. HMG-CoA reductase inhibitors decrease CD11b expression and CD11b dependen tadhesion of monocytes to endothelium and reduce increased adhesiveness of monocytes isolated from patients with hypercholesterolemia. J Am Coll Cardiol 1997;30:1212-17.

18. Weitz-Schmidt G, Welzenbach K, Brinkmann V. Statins selectively inhibit leukocyte function antigen-1 by binding to a novel regulatory integrin site. Nat Med 2001;7:687-92.

19. Durant R, Klouche K, Delbosc S. Superoxide anion overproduction insepsis: effects of vitamin e and simvastatin. Shock 2004;22:34-39.

20. Mayer J, Eller T, Brauer P. Effects of long-term treatment with lovastatin on the clotting system and blood platelets. Ann Hematol 1992;64:196-201.

21. Steiner SM, Speidi WS, Pleiner JM. Simvastatin blunts endotoxininduced tissue factor in vivo. Circulation 2005;111:1841-46.

22. Krysiak R, Okopien B, Herman ZS. Effects of HMG-CoA reductase inhibitors on coagulation and fibrinolysis processes. Drugs 2003;63:1821-54.

23. Laufs U, Endres M, Custodis F. Supression of endothelial nitric oxide production alter withdrawal of statin treatment is mediated by negative feedback regulation of rho GTPasa gene transcription. Circulation 2000;102:3104-10.

24. Laufs U, La Fata V, Plutzky JK. Upregulation of endothelial nitric oxide synthase by HMG CoA reductasa inhibitors. Circulation 1998;97:1129-35.

25. Macin SM, Perna ER, Farias EF. Atorvastatin has an important acute anti-inflammatory effect in patients with acute coronary syndrome: results of a randomized, double-blind, placebocontrolled study. Am Heart J 2005;149:451-57.

26. Weitz-Schmidt G, Welzenbach K, Brinkmann V. Statins selectively inhibit leukocyte function antigen-1 by binding to a novel regulatory integrin site. Nat Med 2001;7:687-92.

27. Frenette PS. Locking a leukocyte integrin with statins. N Engl J Med 2001;345:1419-21.

28. Jialal I, Stein D, Balis D. Effect of hydroxymethyl glutaryl coenzyme a reductase inhibitor therapy on high sensitive C-reactive protein levels. Circulation 2001;103:1933-35.

29. Rice JB, Stoll LL, Li WG. Low level endotoxin induces potent inflammatory activation of human blood vessels: inhibition by statins. Arterioscler Thromb Vasc Biol 2003;23:1576-82.

30. Pruefer D, Makowski J, Schnell M. Simvastatin inhibits inflammatory properties of Staphylococcus aureus alpha-toxin. Circulation 2002;106:2104-10.

31. Mason JC, Ahmed Z, Mankoff R. Statin-induced expression of decay-accelerating factor protects vascular endothelium against complement-mediated injury. Circ Res 2002;91:696-700.

32. Ando H, Takamura T, Ota T, et al. Cerivastatin improves survival of mice with lipopolysaccharide-induced sepsis. J Pharmacol Exp Ther 2000;294:1043-46.

33. Yasuda H, Yuen PS, Hu X, et al. Simvastatin improves sepsis inducedmortality and acute kidney injury via renal vascular effects. Kidney Int 2006;69:1535-42.

34. Merx MW, Liehn EA, Graf JM. Statin treatment after onset of sepsis in a murine model improves survival. Circulation 2005;112:117-24.

35. Chello M, Patti G, Candura D. Effects of atorvastatin on systemic inflammatory response after coronary bypass surgery. Crit Care 2006;34:660-67.

36. Majumdar SR, McAlister FA, Eurich DT, et al. Statins and outcomes in patients admitted to hospital with community acquired pneumonia: population based prospective cohort study. Br Med J 2006;333:999-1001.

37. Spitzer AL, Harris HW. Evidence-base Surgical Hypothesis. Statins attenuate sepsis. Surgery 2006; 139:283-87.

38. Almog Y, Novack V, Eisinger M, et al. The effect of statin therapy on infection-related mortality in patients with atherosclerotic diseases. Crit Care Med 2007;35:372-78.

39. Frost FJ, Petersen H, Tollestrup K, Skipper B. Influenza and COPD mortality protection as pleiotropic, dose-dependent effects of statins. Chest 2007;131:1006-12.

40. Steiner S, Speidi WS, Pleiner J. Simvastatin blunts endotoxin-induced tissue factor in vivo. Circulation 2005;111;1841-46.

41. Hackman DG, Mamdani M, Li P. Statins and sepsis in patients with cardiovascular disease: a population-based cohort analysis. Lancet 2006;367:413-18.

42. Kruger P, Fitzsimmons K, Cook D, et al. Statin therapy is associated with fewer deaths in patients with bacteraemia. Intensive Care Med 2006;32:75-79.

43. Liappis AP, Kan VL, Rochester CG, Simon GL. The effect of statins on mortality in patients with bacteremia. Clin Infect Dis 2001;33:1352-60.

44. Thomsen RW, Riis A, Forum JB, et al. Preadmission use of statins and outcomes after hospitalization with pneumonia: population-based cohort study of 29,900 patients. Arch Intern Med 2008;168(27):2081-87.

45. Thomsen RW, Hundborq HH, Johnson SP, et al. Statin use and mortality within 180 days after bacteremia: a population-based cohort study. Crit Care Med 2006;34:1080-86.

46. Buerke U, Carter JM, Schlitt A, et al. Apoptosis contributes to septic cardiomyopathy and is improved by simvastatin therapy. Shock 2008;29:497-503.

47. Falagas ME, Makris GC, Matthaiou DK, Rafailidis PJ. Statins for infection and sepsis: a systematic review of the clinical evidence. J Antimicrob Chemother 2008;61:774-85.

48. Chua D, Tsanq RS, Kuo IF. The role of statin therapy in sepsis. Ann Pharmacother 2007;41:647-52.

49. Gao F, Linhartava L, Johnston A, Thickett DR. Statins and Sepsis. BJA 2008;100:288-98.